Atea Pharmaceuticals Financial Statements From 2010 to 2022

AVIR -  USA Stock  

USD 6.45  0.47  6.79%

Atea Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Atea Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Atea Pharmaceuticals financial statements helps investors assess Atea Pharmaceuticals' valuation, profitability, and current liquidity needs.
There are over sixty-one available fundamental signals for Atea Pharmaceuticals, which can be analyzed over time and compared to other ratios. Please make sure to validate Atea Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2022 to make sure the trends are evolving in the right direction.
Atea Pharmaceuticals Free Cash Flow is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Free Cash Flow of 341.21 Million. As of 01/21/2022, Tangible Asset Value is likely to grow to about 1.1 B, while Revenue Per Employee is likely to drop slightly above 1 M.

Atea Pharmaceuticals Financial Statements 

 
Refresh
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals main balance sheet or income statement drivers, such as Direct Expenses of 1.4 M, Gross Profit of 43.5 M or Operating Expenses of 74 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0077, PPandE Turnover of 42.93 or Receivables Turnover of 13.11. Atea Pharmaceuticals financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules. It can also supplement various Atea Pharmaceuticals Technical models. Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors.

Atea Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B993.2 M251.1 M
Increasing
Slightly volatile
Cash and Equivalents1.1 B977.6 M247.3 M
Increasing
Slightly volatile
Deferred Revenue269.6 M271.2 M296.6 M
Decreasing
Slightly volatile
Property Plant and Equipment Net43.1 K43.2 K52.3 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables5.2 M5.2 M5.7 M
Decreasing
Slightly volatile
Trade and Non Trade Payables55.4 K54 K325.9 K
Decreasing
Slightly volatile
Total Liabilities391.9 M363.2 M83.9 M
Increasing
Slightly volatile
Shareholders Equity679.7 M630 M114 M
Increasing
Slightly volatile
Current Assets1.1 B993 M250.9 M
Increasing
Slightly volatile
Assets Non Current140.9 K139.5 K158.9 K
Decreasing
Slightly volatile
Current Liabilities391.8 M363.2 M83.8 M
Increasing
Slightly volatile
Liabilities Non Current33.3 K32.4 K117.6 K
Decreasing
Slightly volatile
Shareholders Equity USD679.7 M630 M114 M
Increasing
Slightly volatile
Cash and Equivalents USD1.1 B977.6 M247.3 M
Increasing
Slightly volatile
Accounts Payable134.9 K131.4 K1.3 M
Decreasing
Slightly volatile
Receivables919.1 K895.5 KM
Decreasing
Slightly volatile

Atea Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues43.5 M43.8 M47.9 M
Decreasing
Slightly volatile
Selling General and Administrative Expense26.9 M24.9 M7.9 M
Increasing
Slightly volatile
Research and Development Expense47.2 M43.7 M15.3 M
Increasing
Slightly volatile
Operating Expenses74 M68.6 M23.2 M
Increasing
Slightly volatile
Weighted Average Shares21.1 M24.8 M12.9 M
Increasing
Slightly volatile
Weighted Average Shares Diluted21.1 M24.8 M12.9 M
Increasing
Slightly volatile
Revenues USD43.5 M43.8 M47.9 M
Decreasing
Slightly volatile
Gross Profit43.5 M43.8 M47.9 M
Decreasing
Slightly volatile
Direct Expenses1.4 M1.3 M7.1 M
Decreasing
Slightly volatile

Atea Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing483.7 M611.5 M185.1 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares394.1 M365.3 M107.4 M
Increasing
Slightly volatile
Net Cash Flow from Operations368.2 M341.2 M70.9 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash EquivalentsB952.7 M228.6 M
Increasing
Slightly volatile
Share Based Compensation9.3 M8.6 M2.3 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion21.7 K21.9 K17.9 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(0.0406)(0.0396)0.242
Decreasing
Slightly volatile
Return on Invested Capital0.06650.06486.3395
Decreasing
Slightly volatile
Gross Margin0.890.90.9842
Decreasing
Slightly volatile
Asset Turnover0.09840.0990.1083
Decreasing
Slightly volatile
Sales per Share2.022.032.2168
Decreasing
Slightly volatile
Price to Sales Ratio16.616.718.2577
Decreasing
Slightly volatile
Price to Book Value5.645.676.2014
Decreasing
Slightly volatile
Debt to Equity Ratio0.720.660.1096
Increasing
Slightly volatile
Current Ratio2.532.4614.9349
Decreasing
Slightly volatile
Free Cash Flow per Share17.0515.82.9396
Increasing
Slightly volatile
Book Value per Share31.4829.183.7461
Increasing
Slightly volatile
Tangible Assets Book Value per Share49.6346.013.0049
Increasing
Slightly volatile
Total Assets Per Share2.772.632.3614
Decreasing
Very volatile
Cash Flow Per Share(0.44)(0.41)(0.2811)
Decreasing
Slightly volatile
Receivables Turnover13.1116.5810.4697
Increasing
Slightly volatile
PPandE Turnover42.9349.337.0706
Increasing
Slightly volatile
Cash and Equivalents Turnover0.240.230.339
Decreasing
Slightly volatile
Accounts Payable Turnover51.948.129.4495
Increasing
Slightly volatile
Accrued Expenses Turnover4.124.015.0415
Decreasing
Slightly volatile
Long Term Debt to Equity0.00770.00620.0081
Decreasing
Slightly volatile
Quick Ratio19.3317.9111.6221
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets10310888.4371
Increasing
Slightly volatile
Revenue to Assets0.260.170.243
Decreasing
Slightly volatile

Atea Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization3.1 B3.1 B3.4 B
Decreasing
Slightly volatile
Enterprise ValueBB3.3 B
Decreasing
Slightly volatile
Average Equity309.1 M286.5 M32 M
Increasing
Slightly volatile
Average Assets404.5 M509.3 M126.3 M
Increasing
Slightly volatile
Tangible Asset Value1.1 B993.2 M251.1 M
Increasing
Slightly volatile
Free Cash Flow368.2 M341.2 M70.9 M
Increasing
Slightly volatile
Working Capital679.6 M629.8 M167.2 M
Increasing
Slightly volatile
Revenue Per EmployeeMM872.5 K
Increasing
Stable
Net Income Per Employee(345.7 K)(320.4 K)(488.3 K)
Decreasing
Very volatile

Atea Pharmaceuticals Fundamental Market Drivers

Short Percent Of Float3.98%
Forward Price Earnings-3.46
Shares Short Prior Month6.23M
Average Daily Volume Last 10 Day1.08M
Average Daily Volume In Three Month4.46M
Date Short Interest15th of December 2021
Fifty Day Average8.77
Two Hundred Day Average23.43

Atea Pharmaceuticals Upcoming Events

Upcoming Quarterly Report29th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

About Atea Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atea Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Atea Pharmaceuticals investors use historical funamental indicators, such as Atea Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Atea Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atea Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atea Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue271.2 M269.6 M
Revenues43.8 M43.5 M
Revenue to Assets 0.17  0.26 
Revenue Per EmployeeMM
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.

Atea Pharmaceuticals Investors Sentiment

The influence of Atea Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Atea Pharmaceuticals. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Atea Pharmaceuticals Implied Volatility

    
  184.81  
Atea Pharmaceuticals' implied volatility exposes the market's sentiment of Atea Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Atea Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Atea Pharmaceuticals stock will not fluctuate a lot when Atea Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Atea Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Atea Pharmaceuticals' short interest history, or implied volatility extrapolated from Atea Pharmaceuticals options trading.

Current Sentiment - AVIR

Atea Pharmaceuticals Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Atea Pharmaceuticals. What is your sentiment towards investing in Atea Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Bellus Health. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is Atea Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea Pharmaceuticals. If investors know Atea Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.